The DEEP (DEferiprone Evaluations in paediatrics) project, a 6-year European Project (FP7) coordinated by CVBF and comprising 23 recruiting centres in European and non-European countries, scientific partners from several European countries and a pharmaceutical group based in Canada, is at the final rush and has presented […]
The DEEP project has received research funding from the European Union under the 7th Framework Programme
News
Drug safety of oral iron chelator deferiprone in children: a dissertation on the results of DEEP-3 Study
On September 21st 2017, Sebastian Botzenhardt, researcher involved in DEEP project (DEEP PhD), held the final examination for his doctoral thesis at Friedrich-Alexander-University Erlangen-Nuremberg, where he exposed the overall results of a study aimed to assess the drug safety profile of oral chelator deferiprone (DFP […]
DEEP-3 study results published in the January issue of Haematologica
Sebastian Botzenhardt from University Hospital of Erlangen and his co-writers have just published the results of the DEEP-3 study in the January issue of Haematologica on behalf of the DEEP consortium.
DEEP (Deferiprone Evaluation in Paediatrics) is funded EU-funded project aimed to investigate safety and […]
The pilot study QuBo was presented at the 14th International Conference on Thalassaemia & Haemoglobinopathies and 16th TIF International Conference for Patients & Parents
From November 17th to 19th, 2017, the 14th International Conference on Thalassaemia & Haemoglobinopathies and the 16th TIF International Conference for Patients & Parents took place in Thessaloniki, Greece. In this occasion, the poster of the DEEP (DEferiprone Evaluation in Paediatrics) project discussing the DEEP-2 study informative […]